N itric oxide is well known to play important roles in the regulation of redox signaling through cGMP-dependent pathway. 1 In the past decade, however, it also has been determined to signal through an oxidative post-translational modification of cysteine thiols, S-nitrosylation (SNO, also known as S-nitrosation).
residues are selectively reduced with ascorbate and labeled with biotin-HPDP, allowing the formerly SNO-modified proteins or peptides to be enriched using affinity chromatography. Since then, various labeling reagents [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] have been introduced into the biotin-switch technique with the underlying assumption that labeling of free cysteine residues after the reduction of SNO groups is complete. However, we have observed that there is little overlap in the SNO sites obtained from different proteomic switch experiments, 20 although at the time, these differences were not recognized, indicating that there could be differences in the chemistry between the various labeling reagents and the individual SNO-modifiable cysteine residues.
To investigate this potential labeling bias, we compared SNO-modified cysteine data sets equivalently handled but detected using 2 recently developed isobaric reagents that share same chemical structure except their cysteine-reactive group; cysteine-reactive tandem mass tag (cysTMT) 18, 21, 22 and iodoacetyl tandem mass tag (iodoTMT) 19, 23 ( Figure 1 ). Comparison of these reagents in both cultured cells and cardiac tissues revealed a systemic labeling bias in biotin-switch-style assays that, if not addressed, would result in an incomplete assessment of SNO modifications. These findings also indicate distinct subclasses of reactive SNO residues.
Methods
An extended Methods section is available in the Online Data Supplement.
Cell Lysates and Heart Homogenates Preparation
Human embryonic kidney (HEK) 293 cells were lysed in lysis buffer in the dark. Left ventricles of 8-month-old male C57BL/6 (n=3), 4-to 5-month-old male/female C57BL/6 (n=3), and S-nitrosoglutathione reductase (GSNOR) knockout 24 (n=4) mice were used in this study. Hearts were excised and homogenized on ice in the dark. Protein concentration was determined using the BCA assay (Pierce). 6 HEK cell lysates were diluted to 0.8 g/L in PEN buffer (PBS pH 7.4, 1 mmol/L EDTA, and 0.1 mmol/L neocuproine). For parallel labeling, 400 μg of HEK cell lysate per condition in PEN buffer was treated with 0.1 mmol/L GSNO or 3 different control treatments (untreated vehicle, 0.1 mmol/L reduced glutathione, and 0.1 mmol/L oxidized glutathione for negative controls and untreated vehicle as a positive control) for 20 minutes at 37°C (n=4, from separately cultured plates). GSNO was removed using a Zeba desalt spin column (Thermo) equilibrated with PEN pH 7.4 according to the manufacturer's protocol. The solution of remaining free thiols diluted to 0.5 g/L was blocked with 20 mmol/L of N-ethylmaleimide (NEM) in the presence of 2.5% (wt/ vol) SDS and incubated for 20 minutes at 50°C. Excess NEM was removed by the PEN pH 8.0 equilibrated Zeba desalt spin column. As a positive control, an additional untreated sample (400 μg) was processed but not blocked with NEM. GSNO-treated and control samples were split for labeling with either cys-or iodoTMT 6 (200 μg/each) and half of them (each n=4) were labeled with each sixplex (126-131) of cys-or iodoTMT 6 , individually (n=4 for cysTMT and n=4 for iodoTMT). For cysTMT 6 labeling, samples were diluted to 0.41 g/L in PEN pH 7.4, 1 mmol/L sodium ascorbate, 1 mmol/L CuSO 4 , and 0.3 mmol/L cysTMT 6 (cysTMT 0 in the case of the positive control) and incubated for 2 h at 37°C. For iodoTMT 6 labeling, samples were diluted to 0.41 g/L in PEN pH 8.0, 5 mmol/L sodium ascorbate, and 0.3 mmol/L iodoTMT 6 with equivalent incubation. Excess label was removed by acetone precipitation, and the resultant pellets were carefully washed with an additional volume of acetone. Pellets were resuspended to 1 g/L with PEN and 0.5% of SDS.
TMT Switch Assay With Cys and IodoTMT
Sequential labeling was performed in the iodoTMT 6 -labeling condition. After acetone precipitation, pellets were resuspended with cysTMT 6 -labeling buffer as described and incubated for 2 hours for the second labeling. For simultaneous labeling, samples were incubated with equal concentration of cysTMT 6 and iodoTMT 6 , 5 mmol/L sodium ascorbate, and trace of metals as described in Online Figure VIII .
TMT switch assay with individual recombinant proteins or heart homogenates (450 μg/each) was performed in the same manner as parallel labeling.
TMT switch assay in identical labeling conditions on the 2 labels was performed following the methods for iodoTMT 6 as described above (PEN pH 8.0, 5 mmol/L sodium ascorbate, and 0.3 mmol/L cys-or iodoTMT 6 ), with recombinant protein, HEK cell lysates, and heart homogenates. In these sets of assays, nonreduced condition (no-sodium ascorbate) was used as a negative control. All steps were protected from light.
SNO Peptides Enrichment for Mass Spectrometry Analysis
Elutions from parallel labeling experiments were performed in 2 ways: unlabeled peptides were removed by washing with TBS, and TMT-labeled peptides were eluted with 500 mmol/L triethylammonium bicarbonate pH 8.5 buffer containing 10 mmol/L N,Ndiisopropylethylamine (n=2 in separate 6′plexes for both labels). Or elution was performed as described previously with 50% (v/v) acetonitrile/ 0.4% (v/v) trifluoroacetic acid 18 (n=2 in separate 6′plexes for both labels). Both elution methods were applied alternatively in different replicates to increase TMT peptide identification.
Data Analysis
Raw mass spectrometry (MS) data were searched using OMSSA (version 2.1.9) 25 against the human or mouse Uniprot database. The MS spectra were also searched using the X!Tandem algorithm (version TPP v4.4, rev 1). 26 SNO sites were searched based on FASTA sequence in Uniprot using customized code. Quantitative values for the TMT reporter ions were collected with the Libra module of the transproteome pipeline using a custom condition file (Online Figure  IX) . The fold increase in TMT intensity of GSNO over maximum background signal was indicative of the detected extent of SNO modification and used as intensity index. For experiments performed with nonreduced control (no ascorbate), a site of SNO modification was determined if the TMT intensity in the ascorbate treated sample was greater than the no-ascorbate sample.
The MS data have been deposited to the ProteomeXchange (http://www.proteomexchange.org) via the PRIDE partner repository 27 (PXD000741).
Functional Properties Analysis
Gene ontology-enrichment analysis, molecular function, biological process, and cellular compartment were executed using cytoscape 28 with the Bingo plug-in 29 . In our initial investigations, we found that although the newly developed iodoTMT 6 was effective at labeling cysteine residues, it could not be simply substituted into the previously reported cysTMT 6 switch protocol 18 for SNO modifications ( Figure 1A ; Online Figure IA ). The cysTMT 6 multiplex reagent shares a similar chemical structure that releases the same reporter ions ( Figure 1B and 1C) , and both reagents are enriched by the TMT affinity chromatography. However, cysTMT 6 has a pyridyldithiol-reactive group that forms a reversible disulfide bond with an available cysteine, whereas iodoTMT 6 uses an iodoacetyl group to irreversibly alkylate cysteines. IodoTMT 6 was recently developed to circumvent the reversible cysTMT 6 modification, which would allow iodoTMT 6 -labeled samples to undergo routine reduction and alkylation before MS analysis. 19 To achieve effective incorporation of iodoTMT 6 into the assay, various labeling conditions were evaluated including potential radical initiators or propagators (Online Figure I) . Independently optimized protocols (Online Table I ) were used to detect SNO modifications using the iodoTMT 6 and cysTMT 6 reagents. TMT switch assays were performed on HEK 293 cell lysates treated with 5 different conditions; GSNO to induce SNO, 3 negative control conditions (untreated, reduced glutathione, and Figure 1 . Comparison of the cysteine-reactive tandem mass tag (cysTMT) 6 -and iodoacetyl tandem mass tag (iodoTMT) 6 -labeling reagents. A, Reaction scheme for the TMT switch assay. *Reactions preformed in situ. B and C, Chemical structure of cysTMT 6 (B) and IodoTMT 6 (C). D, Western blot analysis indicating cysTMT 6 and iodoTMT 6 labeling. Both TMTs label S-nitrosylation (SNO) proteins under nitric oxide-inducing conditions. Reduced glutathione (GSH) and S-nitrosoglutathione reductase (GSSG) were used as negative controls. E and F, MS2 spectra (inset) and reporter ions clusters for the same peptide (PC[TMT]SEETPAISPSK, dUTPase nuclear isoform) identified by cysTMT 6 (E) and iodoTMT 6 (F). SNO modification is determined when the S-nitrosoglutathione (GSNO)-treated reporter ion intensity (129 Da) is at least 2-fold greater than greatest control condition: untreated (126 Da), GSH (127 Da), or GSSG (128 Da).
by guest on July 22, 2017 http://circres.ahajournals.org/ Downloaded from oxidized glutathione), and unblocked positive control (labeling of all available cysteine residues). Samples were divided and labeled with cysTMT 6 as previously established 18 or iodoTMT 6 followed by the optimized protocol (see Methods section of this article), in a multiplex format. Then they were subsequently examined by Western blot analysis ( Figure 1D ) or digested, desalted, and analyzed by MS ( Figure 1E and 1F). Analysis of the complete spectral data set resulted in the identification of 1008 unique SNO-modified residues on 773 proteins (Online Tables  II and III ). The iodoTMT 6 reagent identified 648 SNO-modified cysteine residues (corresponding to 495 proteins), whereas cysTMT 6 identified 731 SNO-modified sites in 557 proteins in the same biological samples, handled equivalently (Figure 2A ). Approximately one third of the SNO-modified residues (371 sites) were detected by both of the reagents. A total of 277 SNO-modified cysteine residues were identified exclusively with iodoTMT 6 and this included 200 proteins whose SNO sites were only detected using iodoTMT 6 ( Figure 2A ). When the samples were labeled with either cysTMT 6 or iodoTMT 6 under an identical reducing condition (Methods in the Online Data Supplement), less than one third of the total SNO sites were identified by both of the reagents (Online Table IV ), whereas >60% of the sites were commonly detected between replicates of the same label (Online Figure II) .
Labeling Bias in Classic Biotin-Switch-Style Assay Reveals 2 Subpopulations of cysteine Residues
We have shown that cysTMT 6 and iodoTMT 6 target different cysteine residues in the same experiment, suggesting the possibility for distinct subclasses of cysteine residues. Our data set contained numerous examples, highlighting the specificity of the labeling bias including Cys8 of dynein light chain Tctex-type 3, which was labeled preferentially by cysTMT 6 ( Figure 2C ). Other sites, such as Cys49 of pyruvate kinase PKM, were preferentially labeled by iodoTMT 6 , whereas Cys357 of T-complex protein 1α reacted equivalently to both reagents ( Figure 2B and 2C ).
This labeling bias was validated by a TMT switch assay with recombinant proteins. For example, SNO cysteine residues on human actin was only labeled with iodoTMT, whereas SNO-modified bovine actin was preferentially detected by cysTMT ( Figure 2D ; Online Figure III ).
This observation is further supported by a sequential labeling experiment where SNO sites were first labeled with iodoTMT 6 followed by cysTMT 6 ( Figure 3A ; Online Table  V) . MS analysis detected a group of cysTMT 6 -labeled cysteine residues that remained available throughout the iodoTMT 6 labeling ( Figure 3B ). This finding demonstrates that labeling is not fully saturating and suggests that individual cysteine residues preferentially react with different labeling reagents.
Validation of SNO-Labeling Bias in Mouse Hearts
Next, we applied the dual-reagent protocol and optimized proteomics workflow for MS (discussed in a later section) to identify SNO modifications in mouse hearts. Left ventricular tissue from intact mouse hearts was homogenized, labeled by either iodo-or cysTMT 6 and analyzed through the optimized pipeline as described later. As observed in HEK cell analysis, of the 315 total SNO sites identified, 98 sites were detected with both reagents, whereas 113 sites and 104 sites were 6 or iodoacetyl tandem mass tag (iodoTMT) 6 switch reveals incomplete cysteine labeling. A, Cys-or iodoTMT 6 -labeled SNO sites from human embryonic kidney (HEK) 293 cells were analyzed by MS. The table contains a selection of proteins whose cysteine residues were only detected by iodoTMT 6 . B, MS analysis and quantitation of TMT 6 reporter ions for Cys49 of pyruvate kinase PKM demonstrating the labeling bias (n=4 per group). C, Bar graphs indicating TMT labeling for a selection of SNO-modified cysteines: Cys8 of dynein light chain Tctex-type 3 (n=3 per group), Cys49 of pyruvate kinase PKM (n=4 per group), and Cys357 of T-complex protein 1α (n=3 per group). *P<0.05, ***P<0.00001 by t test. These sites show different preference for either the cys-or iodoTMT 6 reagents. D, Western blot analysis of different TMT labeling on recombinant human actin after cys-or iodoTMT 6 switch assay. Extent of SNO on actin in HEK293 cell was distinguished by MS analysis (Online Table IV ). GSNO indicates S-nitrosoglutathione.
by guest on July 22, 2017 http://circres.ahajournals.org/ Downloaded from identified only with cys or iodoTMT respectively (Online Table VI ). We also performed the switch assay under identical reducing conditions with 4-to 5-month-old wild-type mouse hearts (Online Table VII ). More than 70% of TMT-labeled sites were identified with only 1 tag. Additional 44 sites not identified with cysTMT were determined with iodoTMT, confirming the labeling bias. SNO of muscle proteins such as cardiac troponin I (cTnI) (Cys81), α-actinin-2 (Cys781), and isoform 3 of LIM domain-binding protein 3 (Cys511/Cys514) were exclusively identified via iodoTMT labeling.
Using our 2-label strategy, we were able to confirm SNO modifications previously identified 21, 30, 31 in untreated cardiac tissue and identify several novel modified sites (selected sites are listed in the Table) . For example, cardiac isoform sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA2A), a key protein for Ca 2+ handling, [32] [33] [34] was identified to be S-nitrosylated in this study. It has been reported that the SNO increases the activity of SERCA2A and thus enhances Ca 2+ update into sarcoplasmic reticulum and decreases cytosolic Ca 2+ during ischemia/reperfusion, suggesting SNO-SERCA2A as a potential mediator for cardioprotection. 35 SERCA2A had several SNO-modified cysteine residues previously reported such as Cys364 or Cys471, 21, 30 and also new sites Cys344 and Cys349 were identified in this study, which were exclusively labeled with either of TMT reagents. The other examples, the sites of the muscle proteins described above, Cys781 of α-actinin-2 and Cys511/Cys514 of isoform 3 of LIM domainbinding protein 3, were newly identified to be S-nitrosylated. Without the use of both tags, the detection of SNO modification would be incomplete. On the basis of these data, it is Figure 3 . Sequential cysteine-reactive tandem mass tag (cysTMT) 6 and iodoacetyl tandem mass tag (iodoTMT) 6 labeling for the TMT switch assay in human embryonic kidney cells. A, Scheme depicting sequential labeling methods. B, Mass spectrometry analysis of the sequential labeling found 14% of the S-nitrosylation (SNO) sites were detected by the second label, cysTMT 6 , indicating incomplete labeling by iodoTMT 6 and suggesting distinct subclasses of cysteine residues. NEM indicates N-ethylmaleimide. clear that the addition of an alternate cysteine-reactive tag is required to reduce the labeling bias and thus increase SNO proteome coverage.
Proteomic Profiling of SNO in GSNOR Knockout Mouse
GSNOR is a negative regulator of GSNO in the cell and is thought to govern the SNO level. 36, 37 It has also been identified as a key regulator of cardiac function. 36, 37 Therefore, the GSNOR knockout mouse model was chosen to perform a high-throughput quantitative analysis of SNO modification in mouse hearts and also to highlight the labeling bias across different pools of modified cysteines. By applying the dualreagent protocol, SNO sites in GSNOR knockout hearts were profiled for the first time; a total of 493 SNO sites were identified with either or both of the reagents (Online Table VIII ) and a set of the sites partially overlapped with the sites of wild-type ( Figure 4A ). Of these, SNO sites of widely studied cardiac proteins 38 in the GSNOR knockout hearts were determined.
cTnI is the inhibitory subunit of the troponin complex, which regulates muscle contraction, 39 and is extensively regulated by phosphorylation. 40 cTnI exists as a complex with troponin T and troponin C (cTnC), which is the Ca 2+ -binding subunit. The binding of Ca 2+ to regulatory site of TnC induces a conformational change, which blocks the action of cTnI and generates muscle contraction. 39, 40 Although the functional roles of SNO in those proteins are not well characterized, we site-mapped Cys81 and Cys98 of cTnI and Cys35 of cTnC as S-nitrosylated in GSNOR knockout mice. In addition, 8 SNO sites of SERCA2A and 1 site of ryanodine receptor 2, one of the Ca 2+ handling proteins, 38 were found to be nitrosylated in this model. The SNO proteomes in WT and the GRNOR knockout were further compared based on gene ontology enrichment (Online Table XV) .
Interestingly, the magnitudes of SNO-shift in GSNOR knockout hearts varied across sites because some were hypernitrosylated, whereas others were hyponitrosylated when compared with wild-type. As an example, Cys694 of ceruloplasmin displayed an SNO increase, whereas Cys376 of tubulin α-4A and Cys349 of cardiac isoform SERCA2A were less nitrosylated in GSNOR knockout ( Figure 4B ). A total of 345 sites were hypernitrosylated, and 365 sites were less nitrosylated in the GSNOR-deficient model ( Figure 4C ). These 2 hyper-SNO and hypo-SNO groups were further analyzed based on gene ontology enrichment. Proteins with hyponitrosylated sites in GSNOR knockout were clustered to unique categories, including proteins that have channel or transporter activity or proteins located in extracellular region ( Figure 4D ; Online Figure IV) . The labeling bias in GSNOR knockout hearts was observed to be dominant with cysTMT-labeling over iodoTMT. Presumably, the biased preference to 1 tag occurs by specific cellular chemical environments, which may be different across various biological samples.
Chemical Properties of the 2 Subpopulations
To further investigate the potential subclasses of SNO sites detected by the different reagents, we analyzed the physicochemical properties of the cys-and iodoTMT 6 -specific residues in the HEK and mouse hearts data sets. We hypothesized that a cysteine's reactivity to a particular TMT labeling reagent is dictated by its surrounding chemical environment. Analogous to the selectivity of SNO formation 5, [41] [42] [43] and the chemical properties of neighboring amino acids may affect the likelihood that each cysteine residue will react preferentially with either reagent, whereas the protein's structure determines accessibility. Although these properties were not enough to represent all elements for the environment of a certain reactive cysteine residue, they provide insight into the physicochemical effect.
All amino acid residues flanking each side of the cysteine residues that were specifically reactive to either cys-or iodoTMT 6 from mouse hearts and HEK cell were compared. It revealed that cysTMT 6 -specific sites from hearts had a higher proportion of high theoretical isoelectric point overall than the iodoTMT 6 sites ( Figure 5A ; Online Table IX ). The overall distributions for the isoelectric point were slightly different between the 2 reagents groups from HEK cell (Online Figure V; Online Table IX) . The top 15 reactive (or intense) cysteine residues unique to each reagent were compared; the cysTMT 6 -specific sites were found to have a higher proportion of neighboring positively charged residues (arginine/lysine) than the iodoTMT 6 sites ( Figure 5B ; Online Figure VB ; Online Table IX) .
Next, more global characteristics were investigated for the proteins containing the most reactive (or intense) cysteine that were exclusively labeled by one or the other TMT reagent (Figure 5C and 5D ; Online Table X) . Analysis of aliphatic index revealed that proteins uniquely targeted by cysTMT 6 had a higher number of aliphatic amino acid residues (alanine, valine, isoleucine, and leucine) than those by iodoTMT 6 ( Figure 5C ). Analysis of molecular weight revealed that iodoTMT 6 favored proteins with lower molecular weight than cysTMT 6 group ( Figure 5D ). The analysis with data sets from samples labeled under identical conditions with control groups represented corresponding trends (Online Figure VI) . This suggests a synergic effect between basic sequences and a more local/global hydrophobic structure may produce conditions more favorable to cysTMT 6 than to iodoTMT 6 . The iodoTMT 6 reagent may be more accessible and reactive with cysteine residues located within smaller proteins, local regions with lower pK a , or more global polar character of the intact protein, in both HEK cells and Figure 5 . Physiochemical properties analysis of 2 subpopulations. A, The theoretical isoelectric points (pIs) of 113 exclusively cysteine-reactive tandem mass tag (cysTMT) 6 -labeled residues and 104 iodoacetyl tandem mass tag (iodoTMT) 6 -specific residues from mouse hearts were analyzed and illustrated using a bar graph and a color scale from low (red) to high (green) pI (left, cysTMT 6 ; right, iodoTMT 6 ). Higher proportion of low pI was observed in iodoTMT 6 -specific group (n=3 per group). **P<0.01. B, The frequency of amino acids surrounding the cysteine residues of 2 groups was analyzed (left, cysTMT 6 ; right, iodoTMT 6 ). Valine/leucine and positively charged lysine/arginine were more frequently observed in cysTMT 6 -specific group. Reactive cysteine is highlighted in green at position 11. C, Aliphatic index for proteins (whose cysteine residues were reactive; Online Table X) were computed based on the amino acid sequence and compared between protein groups, which were detected with only 1 TMT reagent. First color scale represents aliphatic index of proteins from human embryonic kidney cell (left, cysTMT 6 ; right, iodoTMT 6 ), and second color scale displays it from mouse hearts. Overall, cysTMT 6 group represented more distribution of higher aliphatic characters. D, Molecular weight of the same proteins for (C) was analyzed and represented in the same way. IodoTMT 6 group had higher proportion of low molecular weight proteins than cysTMT 6 group. cardiac tissue. Although a specific mechanism could not be determined, our findings demonstrate that the reagents can influence selectivity for labeling-specific classes of cysteine residues, presenting at least 2 classes of SNO-modifiable cysteine residues.
Further Optimization of Experimental Strategies to Maximize SNO Detection
To expand the SNO proteome coverage and ensure maximal capture of both subclasses of modified sites, different experimental configurations using both cys-and iodoTMT 6 were evaluated: sequential, simultaneous, and parallel. Sequential labeling starting with either cys-or iodoTMT 6 followed by the other second reagent was determined not to be efficient ( Figure 3B ; Online Figure VII ; Online Table V) . There was reduced TMT intensity for the second reagent along with an increased nonspecific labeling when compared with the single TMT-labeling experiments (Online Figure VII) . This loss of reactivity is likely because of oxidation that accumulates during the additional labeling step. For simultaneous labeling experiments, the reaction conditions needed for efficient iodoTMT 6 labeling was not compatible with those required for optimal cysTMT 6 labeling ( Figure 6A ; Online Figure VIII) . When adapting the cysTMT 6 labeling conditions to be compatible with iodoTMT 6 , the simultaneous labeling was found to be less intense as sum of each single labeling because of poor iodoTMT 6 labeling (Figure 6B and 6C; Online Table XI). We found that labeling with cys-and iodoTMT 6 in parallel had the greatest efficiency to detect SNO sites as it allows preservation of the optimal buffer and reaction conditions for both reagents. Using the individually optimized conditions in parallel for each reagent, we were able to identify ≈700 SNO sites with each labeling reagent, which is more than 2-fold increase when compared with previous cysTMT 6 study using similar conditions. 18 The improvement in individual reagent's SNO identification over the previous study can be attributed to 2 additional features in the method; the use of OMSSA as a search engine for assignment of the MS spectra (Online Table XII ) and the application of new enrichment protocol using a TMT analogue for elution (Online Table XIII ). With MS-based analysis, a total of 1008 SNO-modified residues were identified, through OMSSA search (Figure 2A) . A total of 731 SNO sites in 557 proteins and 648 sites corresponding to 495 proteins were identified with cys-and iodoTMT 6 labeling, respectively (371 sites were detected by both of the reagents). When X!Tandem search engine was applied to the same mass spectra, 315 sites from 271 proteins were found to be SNO with cysTMT 6 labeling and 338 SNO sites corresponding to 274 proteins were identified with iodoTMT 6 labeling (159 sites detected by both TMTs). Overall, OMSSA identified higher number of SNO sites than X!Tandem and had >80% agreement with the X!Tandem data set (Online Table XII ).
Unlike biotin-based labeling, whose labels are removed by reducing agent at enrichment step before MS analysis, 9,14 the elution protocol of TMT preserves the tag during MS analysis. Previously, TMT-tagged peptides were eluted from immune-affinity chromatography by a low pH buffer to denature the interaction between the resin and the TMT peptides. 18 In a new elution protocol, we introduced a small TMT analogue, which interacts with affinity resin to compete the bound TMT peptides. As shown in Online Table XIII, the number of SNO peptides when using the TMT analogue was increased ≈38% over the low pH elution. We applied the new elution protocol in addition to the previous low pH elution method in this study to maximize coverage.
Further investigations indicated the majority of the SNOmodified proteins with a single SNO site and the subcellular locations and molecular functions of them, whose distributions are similar to those of other studies with a single tag (Figure 7 ; Online Table XIV) . 18, 20 On the basis of this, our increased number of total SNO proteins was not derived from the specific detection of a certain functional class of proteins (eg, localized exclusively), and our method increased the depth of proteome coverage. Figure 6 . Simultaneous cysteine-reactive tandem mass tag (cysTMT) 6 or iodoacetyl tandem mass tag (iodoTMT) 6 labeling for the TMT switch assay in human embryonic kidney cells. A, Scheme of simultaneous labeling protocol. B, The efficiency of iodoTMT 6 labeling was assessed for simultaneous labeling. Nonreduced samples are shown in the left and dithiothreitol (DTT)-treated samples are shown in the right. DTT treatment after a coreagent labeling protocol would remove cysTMT 6 (disulfide linked) but not iodoTMT 6 (irreversibly alkylated), revealing the extent to iodoTMT 6 labeling. IodoTMT 6 was found to be less efficient in simultaneous labeling (indicated as combo [2×]) when compared with the single labeling. Total labeled S-nitrosylation (SNO) in simultaneous labeling approach was shown to increase than either cys-or iodoTMT 6 single labeling when the concentration of TMT was double (left) but the efficiency of individual labels decreased than under the optimized conditions for each label, because of poor iodoTMT 6 labeling in both iodoTMT 6 -compatible/incompatible buffers (right). C, Summary of a mass spectrometry analysis from a simultaneous labeling experiment demonstrating poor iodoTMT 6 labeling efficiency. The majority of the detected TMT peptides were labeled with cysTMT 6 . NEM indicates N-ethylmaleimide. 
Discussion
Significant roles of SNO have been proposed in cardiac physiology and pathophysiology. The modification is thought to affect protein function directly by increasing or inhibiting the activity or shield the thiol groups on critical cysteine residues from further oxidation during severe oxidative stress condition such as myocardial ischemia and reperfusion. 8 It is expected that there are other SNO proteins for cardioprotection not identified yet, especially if they are low abundant. 1 In addition, disruption of SNO in myocytes has been recognized as a critical effect in failing hearts. 44 For example, Cys294 of ATP synthase α was found less S-nitrosylated in dyssynchronous heart failure hearts than in cardiac resynchronization therapy hearts. 45 Another example, hyponitrosylation of ryanodine receptor 2 because of imbalance redox, was observed in heart failure and suggested to contribute to diastolic Ca 2+ leak. 46 However, molecular mechanisms and potential therapeutic strategies by SNO in numerous cardiovascular diseases remain incompletely understood. In the aid of better selection among the many existing SNO-labeling reagents such as biotin-HPDP 9 , ICAT 10,17 , SNOSID 11 , SNOCAP 13 , SNO-RAC 14 , d 5 -NEM, 16 cysTMT, 18 and iodoTMT 19 , sets of proteins from 2 different approaches have been compared. 47 We have analyzed the data sets studied with 3 prevalent tags and different experimental protocols, but found little overlaps between them. 20 Thus, in this study, we used same samples with controlled setting where the 2 labeling regents were identical except for their thiol-reactive groups as thioether or alkyl iodide, which are also common in most of other labeling tags. In addition, we analyzed data sets at an amino acid site level for a more accurate comparison. It has been a fundamental assumption of previous studies that these tags and all reactions proceeded to completion, and thus all ascorbate-exposed cysteine were labeled. However, the result of our study demonstrated unsaturation of labeling by an individual label, which has underestimated the number of SNO-modified site. In light of this work, it is important to find a method that allows capture of more sites. Our bioinformatics approach to extract the position of each site allowed site-identification for the corresponding peptides. This has allowed removing peptides' redundancy resulted from miscleavage of peptides, producing a more accurate comparison between the pools of cys-and iodoTMT-modified sites. More importantly, this enabled site-level quantitation, which provided better accuracy over the traditional peptide-level quantitation. Finally, this site-identification has made it possible to extract flanking amino acid sequences of cysteine, which was used for the analysis of consensus sequence and chemical properties.
This study discovered that there are at least 2 unique populations of SNO-modifiable cysteine residues with HEK and cardiac muscles that have distinct reactivity to 2 chemically classified tags. On the basis of this, it is clear that the use of a single tag strategy to detect SNO modifications will introduce a labeling bias. This could affect the interpretation of data and reduce the probability of identification of key modification of proteins because the reactivity of specific set of cysteine residues in a certain environment currently cannot be predicted. To date, all studies on SNO proteomics in the cardiovascular field used only 1 tag, which has led to a presumption that there is only a single SNO-reactive population. Thus, using both reagents will be required to ensure the detection and quantification of 2 subpopulations of an SNO-modifiable cysteine with different chemical characteristics. On the basis of this observation, our optimized parallel workflow is a generalizable method and can be applied to other proteomic investigations using a thiol-labeling switch strategy. The majority of the 1008 SNO-modified proteins had a single SNO site, whereas 24% of them had ≥2 SNO-modified cysteine residues. B and C, Subcellular locations and molecular functions of the proteins were analyzed based on Gene Ontology: Subcellular location of SNO-modified proteins (B) and functional specificity of the SNO-modified proteins (C). These features showed similar distributions to those of other studies for the identification of SNO cysteine 20 or data from our previous study with single cysTMT 18 (data not shown). This indicates that our increased number of SNO proteins is derived from overall proteome, not from a certain class of proteins (eg, localized or functionalized exclusively); further supporting that SNO is able to impact a broad number of subproteomes and various functional classes of proteins.
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Using the dual-labeling strategy, we performed a proteomic profiling of SNO in GSNOR knockout mouse hearts. Previously, most studies have targeted specific SNO modifications. For example, SNO of β-arrestin 2-promoted protein-protein interactions with clathrin in GSNOR knockout mouse spleen. 48, 49 However, few studies have investigated a global change of the entire SNO proteome in a GSNORdeficient model. 37, 50 On the basis of function of GSNOR, levels of SNO in the knockout models were expected to increase overall, but it was not clear whether this would be true across all modified cysteines. Analysis of the ≈500 SNO-modified cysteine residues revealed that although the majority of sites had increased levels of modifications, more than one third were reduced. This implies that SNO regulation is a complex process, and other factors are involved in determining this redox-modification status. Our bioinformatics analysis with the hypo-and hyper-SNO sites suggests that protein functions or subcellular locations may be one of these factors. A set of proteins that contain hypo-SNO sites was uniquely clustered as transporter proteins by gene ontology-enrichment analysis, and this set of proteins was mainly located in membrane or mitochondrion and has metal or nucleotidebinding regions.
In the study, we determined that iodoTMT 6 did not label SNO in the previously reported cysTMT switch protocol. To achieve effective incorporation of iodoTMT into this assay, various labeling conditions were tested and, although we were unable to determine the exact factors that inhibited labeling of iodoTMT 6 compared with cysTMT 6 , our studies successfully optimized conditions for effective iodoTMT 6 labeling. One critical factor was the use of copper during labeling, which has been reported to accelerate ascorbate-dependent reduction of SNO without effecting specificity. 51 However, for iodo-based TMT switch protocols with nitric oxide -inducing conditions, copper over a certain range inhibited iodoTMT 6 labeling, while enhancing cysTMT 6 labeling (Online Figure I) . The alkyl halide moiety in iodoTMT 6 has been indicated to be labile during radical-generating conditions, 52 and labeling was recovered in the presence of 1 mmol/L copper by the addition of glycerol, a known radical scavenger 53, 54 in this study (Online Figure I ). There are several candidates for a radical initiator or propagator in the TMT switch protocol. Some metals have been indicated as a source of radicals similar to those generated in the Fenton-like reaction, 55 and it was reported hydroxyl radicals generated by Cu 2+ /H 2 O 2 were stimulated specifically in HEPES buffer. 56, 57 This could explain the different labeling efficiency observed when labeling was performed in PBS or HEPES buffer. The TMT labeling step is coupled with the reduction of the SNO group by ascorbate, which has been shown to generate hydroxyl radical in copper-contaminated water, 58 suggesting the formation of free radicals that could inhibit labeling.
In conclusion, the parallel combination of both the cysT-MT 6 and iodoTMT 6 increased the coverage of SNO modifications identified; however, comparison of the individual reagent data sets indicated a clear bias in cysteine labeling between the 2 reagents. Each of the TMT reagents has thiol-reactive groups commonly used in the biotin-switch-style assays but have never been rigorously compared. The pyridyldithiol and iodoacetyl reactive groups in the different TMT reagents were found to label distinct but partially overlapping subclasses of cysteine residues. Our findings demonstrate an important but overlooked aspect of labeling in the classic switch assay, which if accounted for, can expand the accessible cysteine proteome.
What Is Known?
• S-nitrosylation (SNO) is a post-translational modification that serves as a key regulator of protein activity in cellular redox status and has many roles in cardiovascular disease, yet the identification and quantification of SNO-modified residues remain limited.
• The biotin-switch technique, which first reduces SNO with ascorbate and then chemically labels newly exposed cysteine residues with a stable tag, has been the most general strategy in this field.
What New Information Does This Article Contribute?
• When using 2 chemically different mass spectrometry-based tags to label the ascorbate-exposed cysteine residues, there are subpopulations of SNO-modified amino acid residues that are preferentially detected by one or the other of the tags, indicating that there has been an unrecognized labeling bias in the common biotin-switch assays.
• An optimized proteomic mass spectrometry-based workflow using 2 (chemically different) tags ensures the detection and quantification of the 2 subpopulations of SNO-modifiable cysteine with different chemical characteristics on the technical side.
• This labeling strategy enables a profiling of nearly 500 SNO sites in cardiac tissue of S-nitrosoglutathione reductase knockout mouse, which is an interesting model for studying redox regulation and reveals that SNO was reduced on one third of the sites, while being increased in the majority.
Investigating site-specific SNO quantification is important because SNO is a protein post-translational modification, which regulates protein activity and responds to cellular redox status. Therefore, the technique to detect SNO has been a long interest in cardiovascular research, and classic biotin-switch style technique has been a widely used method for this. This biotin-switch style techniques shared by a variety of labeling strategies assume that the labeling tag captures all available SNO. However, we show that this is not the case and the labeling bias, which has been unrecognized, exists in the commonly used biotin-switch style assays, allowing to detect only subsets of the SNO-sites. By more accurate amino acid site-level comparison between SNO sites detected by 2 chemically different tags, we provide the evidence that there are different subpopulations of SNO-modifiable cysteine residues, which can only (or preferentially) be detected by 1 labeling reagent. Collectively, we optimize a proteomic workflow using chemically different tags to maximize coverage of the SNO proteome of complex samples such as mouse hearts. We describe an important method that may have a large impact on research practice of all future SNO-based studies, the interpretation of existing SNO data, and our understanding of redox regulation in cardiovascular studies in an unbiased manner. 6 for 2 h at 37 °C. The other half were diluted with equivalent incubation without sodium ascorbate. TMT switch assay with iodoTMT 6 was performed in the same manner as cysTMT 6 labeling. For TMT switch assay with heart homogenates, non-reduced condition (no-sodium ascorbate) was used as a negative control (450 g/each).
All steps were protected from light.
SNO-peptides Preparation for Mass Spectrometry (MS)
Analysis. 200 g of each iodoTMT 6 (or cysTMT 6 ) sample were combined, desalted and digested with trypsin (Promega, 1: 40 of trypsin: protein) 2 . A positive control (all available cysteine residues) sample was processed separately. The digested peptides were incubated with 600 l of the anti-TMT antibody-affinity resin at room temperature for 2 h. Elutions were performed in two ways: Unlabeled peptides were removed by washing with 5 x 5 ml of TBS and TMT labeled peptides were eluted with 3 X 0.6 ml of 500 mmol/L TEAB pH 8.5 buffer containing 10 mmol/L N,Ndiisopropylethylamine. Or elution was performed as described previously with 50% (v/v) acetonitrile /0.4% (v/v) trifluoroacetic acid 2 . Both elution methods were applied alternatively in different replicates to increase TMT peptide identification. Samples were then desalted using solid phase extraction with Oasis HLB (Waters).
Peptide Identification by Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS). LC/MS/MS analysis was performed using an LTQ Orbitrap Velos MS (Thermo Fisher Scientific) interfaced with a nanoAcquity UPLC system (Waters). Peptides from the parallel labeling were fractionated by reverse-phase HPLC on a 75 µm x 15 cm PicoFrit column with a 15 µm emitter (PF3360-75-15-N-5, New Objective) packed in-house with Magic C18AQ (5 µm, 120Å , Michrom) using 0-60% acetonitrile/0.1% formic acid gradient over 90 min at 300 nlmin -1 . Eluting peptides were sprayed directly into an LTQ Orbitrap Velos at 2.0 kV. Isolation width was set to 1.3 Da and normalized collision energy was set to 38. Precursors were acquired at 30,000 resolution and 15,000 and 7,500 for the fragment ions. High energy collision dissociation was used exclusively with a lock mass of the polysiloxane at 371.101230 for MS1 and MS2.
For peptides from sequential and simultaneous labeling and TMT-labeled samples described in in this Online supplemental, LC/MS/MS analysis was performed using an EasynLC 1000 (Thermo Scientific, mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1 % formic acid in acetonitrile) connected to an Orbitrap Elite mass spectrometer (Thermo Scientific) equipped with a nanoelectrospray ion source. Peptides were loaded onto a Dionex Acclaim® PepMap100 trap column (Thermo, 75 µm x 2 cm, C18 3 µm 100Å ) and fractionized on a Dionex Acclaim® PepMap RSLC analytical column (Thermo, 50 µm x 15 cm, C18 2 µm 100Å ) at a flow rate of 300 nLmin -1 using a linear gradient of 2-15% B for 70 minutes, 15-25%for 15 min,25-35% B for 5 minutes, 35-98% B for 2 minutes then holding at 98% for 8 minutes. The nano-source capillary temperature was set to 275 °C and the spray voltage was set to 2.0 kV. MS1 scans were acquired at a resolution of 60,000 FWHM (380-2000 m/z) with Online Figure I . Troubleshooting for iodoTMT labeling. TMT-switch assay was performed with HEK cell lysates. A, TMT-switch assay using cys-and iodoTMT in conditions previously described for cysTMT 2 . Using these conditions, SNO-modified proteins were not labeled with iodoTMT. B, Comparison of cys-and iodoTMT in the TMT-switch assay using optimized conditions (PBS at pH 8.0). The addition of 1mM of copper increased labeling for cysTMT but inhibited iodoTMT labeling. C, TMT-switch assay in the presence of the metal chelator, neocuproine (0.1 and 1 mM) demonstrating the quantitative effect of metal ions on cys-and iodoTMT labeling. D, Decreased iodoTMT labeling by additional 1mM copper was recovered by the addition of 20 mM glycerol, a radical scavenger. E, Various conditions to optimize iodoTMTswitch assay were tested: optimal concentration of iodoTMT, ascorbate and SDS, addition of copper, protein: buffer used for blocking and/or labeling and effect of acetone precipitation.
Online Figure II . Comparison of SNO-sites. A, More than 60% of the sites were commonly detected between two replicates of the same cysTMT B, Less than 30% of the total SNO-sites from HEK cells were identified by both of the reagents. SNO-sites were labeled with either cysTMT or iodoTMT, under identical conditions. Online Figure IX . Libra condition file. When the isobaric tags are released from the manufacturer, each isobaric tag is not 100% pure. Based on the information provided by the manufacturer, correction factors were included in the libra condition file when searching for TMT reporter ion intensities (A: cysTMT labeled samples, B: iodoTMT labeled samples).
